Literature DB >> 18445917

Prevalence of hepatitis C virus infection in hemodialysis patients.

O Taziki1, F Espahbodi.   

Abstract

The prevalence of hepatitis C virus (HCV) infection in hemodialysis patients (HD) has decreased significantly during the past decade in most HD units. To evaluate the cause(s) of this reduction, we studied the HCV antibodies measurements in 1006 HD patients in the Province of Mazandaran, Iran, from January 2001 to December 2006. In December 2001, the prevalence of antibody to HCV was 18%, whereas by December 2006, it decreased to 12%. Causes implicated in the reduction of prevalence of HCV infection in HD patients include a low percentage of new anti-HCV+ patients, a decrease in the conversion rate in HD patients, and more strict infection control measures in the dialysis units.

Entities:  

Mesh:

Year:  2008        PMID: 18445917

Source DB:  PubMed          Journal:  Saudi J Kidney Dis Transpl        ISSN: 1319-2442


  10 in total

Review 1.  Potential for human immunodeficiency virus parenteral transmission in the Middle East and North Africa: an analysis using hepatitis C virus as a proxy biomarker.

Authors:  Yousra A Mohamoud; F DeWolfe Miller; Laith J Abu-Raddad
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

Review 2.  Prevalence of hepatitis C virus infection among hemodialysis patients in the Middle-East: A systematic review and meta-analysis.

Authors:  Soheil Ashkani-Esfahani; Seyed Moayed Alavian; Mohammad Salehi-Marzijarani
Journal:  World J Gastroenterol       Date:  2017-01-07       Impact factor: 5.742

Review 3.  Hepatitis C virus infection in the Middle East and North Africa "MENA" region: injecting drug users (IDUs) is an under-investigated population.

Authors:  S Ramia; N M Melhem; K Kreidieh
Journal:  Infection       Date:  2012-01-12       Impact factor: 3.553

4.  The prevalence of hepatitis C virus in mashhad, iran: a population-based study.

Authors:  Mohammad Taghi Shakeri; Hosein Nomani; Majid Ghayour Mobarhan; Hamid Reza Sima; Sina Gerayli; Shirin Shahbazi; Sina Rostami; Zahra Meshkat
Journal:  Hepat Mon       Date:  2013-03-12       Impact factor: 0.660

5.  Hepatitis C and hepatitis B seroprevalence and associated risk factors in hemodialysis patients in Guilan province, north of Iran: HCV and HBV seroprevalence in hemodialysis patients.

Authors:  Farahnaz Joukar; Sepiedeh Besharati; Hasan Mirpour; Fariborz Mansour-Ghanaei
Journal:  Hepat Mon       Date:  2011-03       Impact factor: 0.660

6.  Hepatitis C and G Virus Infection Prevalence Among Hemodialysis Patients and Associated Risk Factors in the Hormozgan Province of Southern Iran.

Authors:  Ali Kargar Kheirabad; Fahime Bahri; Mohammad Kargar; Iman Ghasemzadeh
Journal:  Hepat Mon       Date:  2016-08-13       Impact factor: 0.660

Review 7.  The epidemiology of hepatitis C virus in Iran: Systematic review and meta-analyses.

Authors:  Sarwat Mahmud; Vajiheh Akbarzadeh; Laith J Abu-Raddad
Journal:  Sci Rep       Date:  2018-01-09       Impact factor: 4.379

Review 8.  Prevalence of hepatitis C infection in Iranian hemodialysis patients: An updated systematic review and meta-analysis.

Authors:  Nahid Ramezan Ghorbani; Shirin Djalalinia; Mitra Modirian; Zahra Esmaeili Abdar; Morteza Mansourian; Armita Mahdavi Gorabi; Hamid Asayesh; Hossein Ansari; Mehrdad Kazemzadeh Atoofi; Ramin Tajbakhsh; Mehdi Noroozi; Saeid Safiri; Mostafa Qorbani
Journal:  J Res Med Sci       Date:  2017-11-28       Impact factor: 1.852

9.  Evaluation of an antigen-antibody "combination" enzyme linked immunosorbent assay for diagnosis of hepatitis C virus infections.

Authors:  E O Odari; N L M Budambula; H Nitschko
Journal:  Ethiop J Health Sci       Date:  2014-10

Review 10.  Epidemiology of hepatitis C virus among hemodialysis patients in the Middle East and North Africa: systematic syntheses, meta-analyses, and meta-regressions.

Authors:  M Harfouche; H Chemaitelly; S Mahmud; K Chaabna; S P Kouyoumjian; Z Al Kanaani; L J Abu-Raddad
Journal:  Epidemiol Infect       Date:  2017-10-09       Impact factor: 4.434

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.